Neovacs (ALNEV) EUR0.0005
Sell:€0.28Buy:€0.39
€0.01
(3.30%)
- This stock can be held in a
Stocks and Shares ISA€0.01
(3.30%)€0.01
(3.30%)Company Information
About this company
Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Key people
Key facts
- EPIC-
- LocationFrance
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINFR001400TG47
- Market cap€80,850.00
- Employees22
- Shares in issue9.34m
- ExchangeEuronext Paris
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.